Clinical Trial Spotlight

A New Way to Target Childhood Cancer?

Researchers are studying a targeted immunotherapy for children with high-risk or relapsed neuroblastoma.

What is Neuroblastoma?

Neuroblastoma is a cancer that develops from immature nerve cells. Key facts include:

  • It most commonly affects infants and young children.
  • It can start in the adrenal glands or nerve tissue in the abdomen, chest, neck, or spine.

Why Are New Treatments Needed?

The standard journey includes diagnosis, treatment, and remission. However, some children experience relapse or their cancer stops responding to treatment. Because high-risk diseases have limited remaining options, new pathways are urgently needed.

Meet Naxitamab

Targeting GD2

Naxitamab is an antibody designed to target a specific marker called GD2, which is found on the surface of neuroblastoma cells.

How Does It Work?

  1. Naxitamab finds GD2 on the cancer cells.
  2. It binds directly to the cancer cell.
  3. It alerts the patient's immune system.
  4. Immune cells help attack and destroy the cancer cell.
Why Researchers Are Excited
Traditional Treatments Targeted Immunotherapy
May affect healthy cells Targets cancer cells more precisely
More side effects Works with the immune system
Less targeted Potentially fewer off-target effects

Stay Informed. Stay Hopeful.

Clinical trials help answer important questions and may lead to new, better treatments for children with cancer. Every clinical trial brings us closer to better options for children and families.

Learn more about this study:

NCT06013618